Mersana Therapeutics Inc
MRSN - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$145.36M
Close$
$-1.14
103.9% downside
Current Fair Value
103.9% downsideOvervalued by 103.9% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $145.36 Million |
|---|---|
| Enterprise Value | $115.04 Million |
| Earnings per Share | $-14.12 |
| Beta | 0.43 |
| Outstanding Shares | 4,986,784 |
Return
| Return on Equity | 117.71% |
|---|---|
| Return on Assets | -111.80% |
| Return on Invested Capital | -309.96% |
Valuation & Multiples
| P/E Ratio | -4.56 |
|---|---|
| PEG | 13.25 |
| Price to Sales | 4.85 |
| Price to Book Ratio | -2.42 |
| Enterprise Value to Revenue | 3.47 |
| Enterprise Value to EBIT | -1.91 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.23 |
| Debt to Equity | -0.44 |
Revenue Sources
No data
Last Earnings Call
Report Date
March 2, 2026
EPS Estimate
$-3.05
Consensus analyst estimateRevenue Estimate
$4.60 M
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | 30,400▲ Infinity% |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 45.01%▼ 18.73% |
|---|---|
| Total Invested | $64.77M▲ 162.65% |
| Investors Holding | 50▲ 1.00% |
About Mersana Therapeutics Inc
CEO: Anna Protopapas
